30results about How to "Good immune effect" patented technology

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

The invention belongs to the technical field of biology, and discloses a recombinant turkey herpesvirus co-expressing an avian influenza H9 gene and an avian adenovirus 4 type Fiber-2 gene, the H9 gene containing a promoter and a terminator is inserted between an HVT053 site and an HVT054 site of the turkey herpesvirus, the Fiber-2 gene containing a promoter and a terminator is inserted between an HVT087 site and an HVT088 site of the turkey herpesvirus, and the recombinant turkey herpesvirus co-expressing the avian influenza H9 gene and the avian adenovirus 4 type Fiber-2 gene is obtained. The recombinant virus is obtained. The recombinant turkey herpesvirus can stably co-express the H9N2 subtype avian influenza virus H9 protein and the fowl adenovirus 4 type Fiber-2 protein, has very excellent immune performance, and effectively improves the immune effect of the recombinant virus of the traditional fowl adenovirus Fiber-2 gene; compared with the recombinant herpesvirus of turkey which singly expresses any one of the H9N2 subtype avian influenza virus H9 protein and the fowl adenovirus 4 type Fiber-2 protein, the recombinant herpesvirus of turkey has the advantage that the performance of the recombinant herpesvirus of turkey is not weakened. Meanwhile, the invention also provides application and a vaccine of the recombinant herpesvirus of turkeys.

The invention belongs to the technical field of bioengineering, and particularly relates to a cat hair allergy recombinant fusion protein as well as a preparation method and application thereof. The method comprises the following steps: analyzing and screening B cell epitopes of the cat hair allergic protein, carrying out series fusion expression on Feld1, Feld3, Feld4, Feld7 and Feld8 and the B cell epitopes of the allergic protein, optimizing escherichia coli codons, and realizing high-efficiency expression in an escherichia coli expression system; the fusion expression scheme not only has higher protein expression, but also enhances the immunogenicity due to the connection with the own B cell epitope. A plurality of cat hair allergy recombinant fusion proteins with strong immunogenicity are adopted to carry out subcutaneous immunization on laying hens to obtain corresponding high-titer broad-spectrum egg yolk antibodies, allergy proteins can be effectively neutralized, the egg yolk antibodies are used for preparing functional cat food or additives, and allergic reactions of animals and contact personnel can be reduced.

The invention discloses a preparation method of a chicken DKK1 protein polyclonal antibody, and relates to the technical field of poultry genetic engineering, and the method comprises the following steps: (1) constructing a chicken DKK1 gene recombinant expression plasmid by using nucleotide as shown in SEQ ID No.1 and a prokaryotic expression vector; (2) transforming the chicken DKK1 gene recombinant expression plasmid into a host cell, then performing screening and induced expression to obtain a His-DKK1 fusion protein, and purifying the His-DKK1 fusion protein; and (3) immunizing an animal with the purified His-DKK1 fusion protein, and performing serum separation and purification to obtain the chicken DKK1 protein polyclonal antibody. The invention also provides an application of the chicken DKK1 protein polyclonal antibody in a chicken DKK1 protein detection reagent or kit. The DKK1 protein in chicken tissues in different development stages can be specifically recognized, and an important tool is provided for functional research of DKK1 on chickens.

The invention relates to the field of biological medicine, in particular to a recombinant herpes zoster vaccine composition and a preparation method thereof. The recombinant herpes zoster vaccine composition comprises gE protein and an adjuvant, the adjuvant is a squalene oil-in-water adjuvant, and the squalene oil-in-water adjuvant comprises the following components by concentration: 4-5wt% of squalene, 1-5wt% of gE protein, 1-5wt% of gE protein, 1-5wt% of gE protein, 1-5wt% of gE protein, and the balance of water. 0.2 to 0.8 wt% of Tween 80; and 0.2 to 0.8 wt% of Span 85. The vaccine composition disclosed by the invention can specifically enhance cellular immune response aiming at the varicella-zoster virus, can remarkably improve expression of cytokines such as INF-gamma and IL-2 of CD4 + T cells of mice, improves the immune response level of body fluid and cells at the same time, shows high immunocompetence for preventing clinical varicella-zoster virus infection, and has good clinical application prospects. And the components in the vaccine composition are cheap and easy to obtain, so that the vaccine yield is effectively improved, and the vaccine cost is reduced.

The invention relates to the technical field of feed, and discloses a feed additive for laying hen breeding and a preparation method thereof.The feed additive for laying hen breeding is obtained by drying vitamins, nicotinamide, an antioxidant butylated hydroxytoluene, calcium pantothenate, modified chitosan and liquorice, putting the materials into a stirrer, conducting smashing and then conducting mixing. The feed additive obtained by compounding the raw materials can promote the growth of laying hens and promote the organ development of the laying hens; the oxidation resistance and the immunocompetence of the laying hens are improved; amino acid and chitosan groups contained in the modified chitosan also play a better role in helping the growth of the laying hens. The feed additive can shorten the laying day age of laying hens, improve the laying rate, improve the quality of eggs, reduce the yield of inferior eggs, improve the body quality of the laying hens and the like, is a non-toxic, drug-resistant and residue-free laying hen feed additive, and can be widely applied to laying hen feeding feeds.

The invention discloses a composite adjuvant, and belongs to the field of vaccine adjuvants. The main active components of the composite adjuvant are squalene, polysorbate 80 and monophosphoryl ester A, the composite adjuvant is in an oil-in-water emulsion form, nano-scale emulsion droplet particles are uniformly distributed in a water phase, and the system is stable. The invention also discloses a preparation method of the composite adjuvant based on a stirring method. The composite adjuvant comprehensively utilizes the dual characteristics of the oil-in-water emulsion and the immunopotentiator, and can induce a higher level of immunoreaction when being combined with the antigen, so that the composite adjuvant can be used for preparing vaccines and improving the effectiveness of the vaccines.

The invention discloses a composition for treating infantile eczema and a preparation method and application thereof.The composition for treating infantile eczema is prepared from, by mass, 60-80 parts of aloe vera gel, 7-9 parts of peach leaf extract, 1-2 parts of codonopsis pilosula extract, 6-8 parts of duckweed extract, 2-3 parts of vitamin C and 1-2 parts of dipotassium glycyrrhizinate. The aloe vera gel, the peach leaf extract, the codonopsis pilosula extract, the duckweed extract, the dipotassium glycyrrhizinate and the vitamin C are compounded, the components are simple, the medicine effect is definite, and the aloe vera gel and the dipotassium glycyrrhizinate mainly provide anti-inflammation and antibacterial effects; the peach leaves and the vitamin C provide antioxidant protection; codonopsis pilosula and vitamin C can promote immunity and skin repair. The duckweed helps to relieve symptoms and regulate the in-vivo environment, and the condition of infantile eczema can be controlled and improved more comprehensively through multi-aspect treatment strategies.

The invention provides a pertussis (five components), diphtheria and tetanus combined vaccine, and particularly relates to a pertussis and tetanus combined vaccine with improved immune response. The immunogenic composition and the vaccine provided by the invention contain specially selected double aluminum-based adjuvants, so that the prepared composition vaccine can induce an organism to generate a good immune response, and meanwhile, the safety of the vaccine is ensured.

The application discloses a fusion protein and a preparation method and application thereof. The fusion protein comprises a P1 protein C-terminal fragment and an adjuvant protein, and can be used for preparing a Mycoplasma pneumoniae recombinant protein vaccine. The P1 antigen fragment is fused and expressed with a mucosal adjuvant, so that high expression quantity, strong immunogenicity and induction of respiratory mucosal immune response are realized.

The present invention relates to the field of biomedicine, and in particular to a serotype 4 avian adenovirus strain, a vaccine, a vaccine composition, a multi-unit vaccine and applications thereof. The serotype 4 avian adenovirus strain of the present invention has a deposit number of CGMCC No.45070. The Hexon gene sequence of the strain of the present invention is shown in SEQ ID NO:1. The present invention also relates to a vaccine, a vaccine composition and a multi-unit vaccine prepared using the strain. The strain of the present invention has high pathogenicity, with a lethality rate of 100% for 21-day-old SPF chickens, and the vaccine and vaccine composition prepared using the strain have good immune protection.

The application discloses a phosphoric acid modified protein or polypeptide, a preparation method thereof and application thereof in vaccines, and belongs to the field of protein phosphoric acid modification. The preparation method of the phosphoric acid modified protein or polypeptide is as follows: a compound containing an aldehyde group and a phosphate group is subjected to nucleophilic reaction with a protein or polypeptide to form a Schiff base; a reducing agent is used to reduce the Schiff base, and after post-treatment, the phosphoric acid modified protein or polypeptide is obtained. After the phosphoric acid modified protein product prepared by the method is prepared into a vaccine with an aluminum hydroxide adjuvant and mice are immunized, the antibody titer is significantly increased. This is of great significance for increasing the immune effect, reducing the inoculation dose, saving the antigen amount and improving the immune response of some people or in specific conditions.

The invention belongs to the technical field of molecular biology, and particularly relates to a recombinant vector for expressing OrfV truncated F1L protein, a strain and application of the recombinant vector. The preparation method comprises the following steps: truncating an F1L gene of an orf virus, introducing a His tag and a termination codon sequence, and constructing into a pYD1 plasmid to obtain a pYD1-F1L recombinant plasmid; and introducing the recombinant plasmid into competent cells of saccharomyces cerevisiae to obtain the recombinant yeast strain. According to the invention, the F1L gene of OrfV is truncated, so that the immunogenicity of the OrfV is effectively retained; the anchoring protein is displayed on the surface of the saccharomyces cerevisiae, so that the immune function of the saccharomyces cerevisiae can be developed; recombinant saccharomyces cerevisiae is adopted as a delivery carrier, the antigen protein can better play an immune role by means of the constant value of the recombinant saccharomyces cerevisiae in intestinal tracts, and meanwhile, the risk that the F1L protein is degraded by protease when being orally taken is further reduced. The invention provides a new direction for the development of OrfV oral vaccines.

The present invention discloses a method for constructing a DNA vaccine for co-expressing Marek's disease virus glycoprotein gC and gD. It belongs to the technical field of DNA molecular vaccines. It includes: Marek's disease virus glycoprotein gC and gD genes, IL-18 gene, self-cleavage polypeptides P2A and T2A, and eukaryotic expression vectors, and provides a construction method and application. The operation method of the present invention is simple, the preparation time is short, and large-scale production can be carried out; the homologous sequence between the vector and the target gene is recombined by a recombinase, and the PCR cloned product can be directly used for recombination, and the three target genes are expressed separately; it is conducive to the processing and presentation of the product of the antigen gene in the body; it is safe and reliable, and easy to store and transport. Animal experiments show that the weight of three yellow chickens immunized with DNA vaccines increases normally, no side effects occur, and the immunized chickens produce obvious humoral immunity and cellular immune responses.

The present invention relates to a novel goose astrovirus vaccine and a preparation method and application thereof. According to the coding sequence of the CAP gene of goose astrovirus, the CAP protein fragment coding gene is determined by analyzing its conservative region and the dominant antigen epitope structure region. The CAP protein fragment is successfully expressed and purified in Escherichia coli, and a subunit vaccine of goose astrovirus is further prepared. Immunization experiments show that the prepared subunit vaccine can protect goslings, and even for goslings initially infected with the virus, it has the effect of further killing the virus in vivo. The goose astrovirus subunit vaccine of the present invention has the advantages of simple preparation method, low production cost and good immune effect, and is suitable for various poultry, such as chickens, ducks and geese, for the prevention and treatment of astrovirus.

The present invention belongs to the field of genetic engineering technology, and specifically relates to an anti-ASFV P30 protein monoclonal antibody and its application. The present invention provides an anti-ASFV P30 protein monoclonal antibody, wherein the anti-ASFV P30 protein monoclonal antibody has a heavy chain sequence as shown in SEQ ID NO: 1 and a light chain sequence as shown in SEQ ID NO: 2. The anti-ASFV P30 protein monoclonal antibody of the present invention not only has high specificity and sensitivity, but also has a simple preparation process and low cost, and provides a new and powerful tool for the rapid diagnosis of ASFV.

The present invention discloses a microneedle patch loaded with dacarbazine and manganese salt, a preparation method thereof, and an application in the treatment of melanoma, wherein the microneedle patch comprises a back-symmetric layer and a needle array arranged on the back-symmetric layer, wherein the back-symmetric layer and the needle array are both formed by an aqueous solution of a degradable polymer, and dacarbazine and manganese salt are loaded in the aqueous solution of the degradable polymer used to form the needle array. The drug-loaded microneedles obtained by the present invention can effectively inhibit the growth and metastasis of tumors, effectively prevent the recurrence of tumors, and achieve efficient killing of melanoma.

The invention belongs to the technical field of biological genetic engineering, and particularly relates to a subunit oral vaccine for ricefield eel rhabdovirus and application. The G protein antigen sequence of the ricefield eel rhabdovirus is decomposed and screened, the linker protein and the N protein of the ricefield eel rhabdovirus are combined in series, and two proteins with the highest fusion protein expression quantity are selected through a baculovirus expression system. And further performing immunogenicity screening to find that the immune effect of the G2-N is optimal, and finally taking the G2-N as a finless eel rhabdovirus oral vaccine. The oral ricefield eel rhabdovirus vaccine is provided for the first time, after the vaccine is orally taken for counteracting toxic substances, the protection rate of the vaccine can reach 90% through seven-day observation, and infection of ricefield eel rhabdovirus can be effectively prevented.

The invention discloses a particle carrier sustained-release vaccine and application thereof. The particle carrier sustained-release vaccine is a self-healing microsphere combined with an aluminum adjuvant; antigens are loaded inside and outside the self-healing microspheres. The preparation method of the particle carrier sustained-release vaccine comprises the following steps: preparing blank porous microspheres by a multiple emulsion emulsification solvent volatilization method, a microfluidic technology, a spray drying method, a salt dissolution method and the like, and loading an aluminum adjuvant adsorbed with an antigen into the blank porous polymer microspheres in a physical diffusion and electrostatic adsorption manner, so as to prepare the particle carrier sustained-release vaccine. Finally, the microspheres are self-healed through the characteristics of the polymer, so that the antigen is divided into an inner part and an outer part. After the particle carrier sustained-release vaccine enters a body, relatively continuous antigen sustained release is respectively carried out in different time periods; the prepared vaccine can effectively collect and activate antigen-presenting cells, release antigens and be taken in by the antigen-presenting cells, so that immune response is caused, generation of specific antibodies is induced, and immune memory is formed.

This invention belongs to the field of genetic engineering technology, specifically relating to a double-gene-deleted serotype 5 Haemophilus parasuis attenuated vaccine strain, its construction method, and its application. This invention mainly utilizes modern genetic engineering principles and molecular biology techniques to delete the cpxA and cpxR genes, potential virulence factors of HPS, constructing the HN1570 double-gene-deleted strain HPS5△cpxAR. This double-gene-deleted strain was deposited at the China General Microbiological Culture Collection Center (CGMCC) on June 16, 2023, with accession number CGMCC NO: 45596. Compared with the parent strain, this double-gene-deleted strain exhibits significantly reduced virulence while maintaining the same immunogenicity. The attenuated live vaccine prepared from this strain as an antigen provides 100% protection against serotype 5 infection and good cross-protection against other serotypes and untyped Haemophilus parasuis infections. Furthermore, the vaccine preparation process eliminates the need for inactivation and inactivation testing, simplifying the preparation method and increasing production efficiency. This lays the foundation for further development of novel, highly effective genetically engineered live vaccines that provide high cross-protection efficacy.

The invention provides an immunogenic composition and a pertussis (three components), diphtheria and tetanus combined vaccine, and particularly relates to a pertussis-pertussis vaccine capable of improving immune response. The immunogenic composition and the vaccine provided by the invention contain specially selected double aluminum-based adjuvants, so that the prepared composition vaccine can induce an organism to generate a good immune response, and meanwhile, the safety of the vaccine is ensured.

This invention belongs to the field of feed additive technology, specifically relating to a microalgae compound feed additive for alleviating weaning stress in calves and its preparation method. The microalgae compound feed additive comprises the following raw materials in parts by weight: 5-10 parts microalgae powder, 2-6 parts unsaturated fatty acid / modified montmorillonite complex, 0.7-1.2 parts probiotics, and 0.3-0.5 parts walnut shell extract. This microalgae compound feed additive can improve the fragile intestinal barrier function and immunity of weaned calves, enhance their growth performance, and thus improve breeding efficiency.

This invention relates to the field of animal immunology, and more particularly to an antigen that enhances the immune response to Newcastle disease virus (NDV), its preparation method, and its application. The antigen is a fusion protein obtained by expressing the Ii-key-F-Fc recombinant vector using engineered bacteria, named the Ii-key-F-Fc fusion protein. The Ii-key-F-Fc recombinant vector is obtained by splicing three major antigenic epitope fragments from the NDV F protein and then tandemly connecting them with chicken IgY Fc and Ii-key. This invention constructs the pCold-TF-Ii-key-F-Fc prokaryotic expression plasmid by tandemly connecting the novel chicken vector Ii-key-Fc with the F antigenic epitope, and then expresses the fusion protein using an E. coli expression system to obtain a new antigen that enhances the immune response in poultry. This provides a new approach for developing a novel NDV vaccine and a new strategy for improving the immune response of subunit vaccines in poultry.

The application discloses an antibacterial peptide Ajaponin of Japanese eel and application thereof. The antibacterial peptide Ajaponin is composed of 21 amino acids and has a molecular weight of 2693.29 Dalton. The antibacterial peptide Ajaponin contains 7 positively charged amino acid residues, has a hydrophobicity of 0.316 and an isoelectric point of 11.45. The antibacterial peptide Ajaponin is a novel cationic short peptide, has good water solubility, high antibacterial activity, low toxicity and other advantages, is composed of limited amino acid residues, has compact structure, is easy to synthesize and purify, and is convenient for large-scale production and application. In addition, the antibacterial peptide Ajaponin contains multiple positively charged amino acid residues, is beneficial to interaction with negative charges of bacterial cell membranes, destroys the membrane integrity, and thus plays a role in rapid bacteriostasis and sterilization.

To provide a pharmaceutical composition capable of enhancing the effect of an immune checkpoint inhibitor against tumor or cancer in a subject. Provided is a pharmaceutical composition that comprises bacterial cells, a culture supernatant, a metabolite, and / or a bacterial cell extract of Ruminococcaceae enterobacterium, and is administered in combination with an immune checkpoint inhibitor.

The invention discloses a bovine herpesvirus type 4 virus strain and application thereof, the bovine herpesvirus type 4 virus strain is a bovine herpesvirus type 4 CB strain, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.45255, and the preservation date is August 10, 2022. The bovine herpesvirus type 4 inactivated vaccine is safe in application and has a good immune protection effect on bovine herpesvirus type 4 diseases caused by the bovine herpesvirus type 4. The immunized cattle can be protected for at least four months.

The invention discloses a non-antibiotic antibacterial growth-promoting feed additive for animals and application of the non-antibiotic antibacterial growth-promoting feed additive. The invention relates to a TBHQ (tert-butyl hydroquinone)-carvacrol emulsion which comprises the following components in percentage by weight: 25.0 to 35.0 percent of TBHQ, 25.0 to 35.0 percent of carvacrol, 3.0 to 10.0 percent of vanillin, 25.0 to 40.0 percent of vegetable oil, 0.05 to 0.1 percent of neotame and 2.0 to 5.0 percent of emulsifying solubilizer. The feed is suitable for species including but not limited to pigs, chickens, ducks, quails, pigeons, rabbits, sheep, cattle, fishes, shrimps and the like. In the aspect of improving the immunocompetence and production performance of livestock and poultry, the invention shows an excellent effect, and provides a solid technical basis for non-antibiotic bacteriostatic feed additives.

The invention belongs to the field of tumor immune cell therapy, and discloses a mononuclear cell culture P-DC cell for tumor therapy, a preparation and a culture method, and the culture method comprises the following steps: singly collecting mononuclear cells; the volume is 20 to 30 ml; culturing P-DC cells in an immature state in a laboratory for about 7 days; an immune synergist P-L is added in the process of culturing the DC cells. Reagents for culturing the DC cells are completely localized, so that the cost for treating tumors is greatly reduced, and huge medical insurance cost can be saved for the country. As the P-DC cells are exact in curative effect, free of side effects and free of dependence, the conditions of numerous middle and late stage cancer patients can be rescued and reversed. The effects of relieving the pain of the cancer patient and prolonging the life can be achieved to the minimum extent according to the illness state and different development stages of the cancer patient, and the social benefits cannot be measured by money.

The invention relates to the field of biological medicine, in particular to free ALU115 and ALU247 complete antigens, a monoclonal antibody and application of the free ALU115 and ALU247 complete antigens and the monoclonal antibody. The complete antigen is formed by coupling an ALU hapten and a protein carrier, and the ALU hapten is an ALU115 nucleic acid fragment and an ALU247 nucleic acid fragment containing amino labels. And a monoclonal antibody obtained by the complete antigen immunization. The invention also discloses an application of the monoclonal antibody in preparation of a product for detecting ALU115 and ALU247. The ALU115 and ALU247 complete antigen and the monoclonal antibody obtained through immunization of the ALU115 and ALU247 complete antigen are disclosed for the first time, the immune effect of the complete antigen is good, the obtained monoclonal antibody has high specificity, and a reliable method is provided for promoting clinical detection of ALU115 and ALU247; the monoclonal antibody provided by the invention can be used for detecting the existence of ALU115 and ALU247 at high sensitivity.

This invention discloses a pre-fusion F protein of respiratory syncytial virus (RSV) and its applications. The pre-fusion F protein is a recombinant pre-fusion F protein of RSV modified with amino acid mutations. The mutation modification method is selected from any of the following: (1) point mutation of amino acids based on the full-length sequence of wild-type pre-fusion F protein; (2) first deleting the transmembrane / intracellular region of the full-length sequence of wild-type pre-fusion F protein, and then attaching the fibritin / Throm / 6his / Stretaq sequence to its C-terminus, and then mutating K at amino acid position 75 to C and S at amino acid position 215 to C. This invention utilizes protein genetic engineering techniques to rationally optimize the amino acid sequence of the pre-fusion F protein of RSV. Compared with the wild-type F protein, the pre-fusion F recombinant protein modified with amino acid mutations has improved stability and immunogenicity.